← Eichor
Study identifier: NCT07463872 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Management of Pancreatic Cystic Lesions Using Artificial Intelligence Based on EUS and Multimodal Data

Condition: Pancreatic Cystic Lesion · Mucinous Cystadenoma of Pancreas · Intraductal Papillary Mucinous Neoplasm of Pancreas  ·  Sponsor: Huazhong University of Science and Technology

PhaseN/A
Planned participants500
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

The primary objective is to construct a multimodal AI model (Cyst-AI) based on EUS images and clinical data such as imaging features(CT or MRI) and laboratory tests to assist endoscopists in the diagnosis of pancreatic cystic lesions(PCLs), mainly differentiating mucinous from non-mucinous lesions. The secondary objective is to evaluate the model's effectiveness in risk stratification and clinical management for patients with PCLs.

This description comes directly from the study's public registry record.

Talk to the study team

Bin Cheng  ·  86-13986097542  ·  b.cheng@tjh.tjmu.edu.cn

Always discuss trial participation with your own doctor first.

Locations (2)

Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, ChinaNot Yet Recruiting
Tongji Hospital, Tongji Medical College, Huazhong University of Science and TechnologyWuhan, Hubei, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07463872